Edition:
United States

Merus Labs International Inc (MSLI.OQ)

MSLI.OQ on NASDAQ Stock Exchange Capital Market

0.80USD
25 Apr 2017
Change (% chg)

$0.04 (+5.26%)
Prev Close
$0.76
Open
$0.80
Day's High
$0.80
Day's Low
$0.80
Volume
1
Avg. Vol
4,272
52-wk High
$1.76
52-wk Low
$0.72

Latest Key Developments (Source: Significant Developments)

Merus Labs responds to Reuters News article
Tuesday, 28 Feb 2017 10:40pm EST 

Merus Labs International Inc : Merus Labs responds to Reuters News article . Currently using Rothschild to provide investment banking and financial advisory services . Merus Labs International - Aware of a news story from Reuters suggesting that it has hired Rothschild & Co. to explore strategic alternatives . Merus Labs-Rothschild supporting Co in evaluation of broad range of options related to capital structure, product acquisitions, corporate deals .Merus Labs International - Does not intend to comment further except as required by applicable securities laws or policies of Toronto Stock Exchange.  Full Article

Merus Labs reports Q3 2016 results
Monday, 15 Aug 2016 07:00am EDT 

Merus Labs International Inc : Merus Labs reports fiscal q3 2016 results . Q3 revenue view c$27.2 million -- Thomson Reuters I/B/E/S . Revenue increased to $25.7 million for fiscal q3 2016 from $9.5 million in prior year quarter . Higher than planned expenses during second half of current fy to result in fiscal 2016 adjusted ebitda $43 million - $46 million .For fiscal q3 2016, merus incurred a net loss of $5.1 million compared to a net loss of $1.8 million for prior year period.  Full Article

Merus says pound depreciation to marginally impact EBITDA
Monday, 4 Jul 2016 07:00am EDT 

Merus Labs International Inc : Merus announces reduced leverage and provides business update . Recent depreciation of pound sterling post Brexit vote is expected to impact company's EBITDA by approximately 1 pct . Sees 2016 adjusted EBITDA, without consideration of additional acquisitions, to be in $47 million to $50 million range . Integration plans with previously acquired products from Novartis, UCB and Sanofi remain on schedule . Says less than 10% of merus' total sales are in UK .Reiterating its 2016 guidance.  Full Article

Merus Labs International says Michael Bumby appointed CFO
Thursday, 30 Jun 2016 04:00pm EDT 

Merus Labs International Inc : Says Michael Bumby appointed CFO succeeding Andrew Patient .Bumby was most recently CFO of Acerus Pharmaceuticals Inc.  Full Article

Merus BV prices IPO at $10 per share
Wednesday, 18 May 2016 08:49pm EDT 

Merus Bv : Pricing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share .Says Citigroup Global Markets Inc and Jefferies LLC are acting as joint book-running managers for offering.  Full Article

Merus Labs reports fiscal Q2 2016 results
Wednesday, 11 May 2016 04:09pm EDT 

Merus Labs International Inc : Qtrly net revenue of $19.7 million, a 55 pct increase over Q2 2015 . Sees 2016 adjusted EBITDA, without consideration of additional acquisitions, to be in $47 million to $50 million range . For fiscal Q2 2016, company incurred a net loss of $3.4 million .Merus Labs reports fiscal Q2 2016 results.  Full Article

Merus Labs International Inc announces inaugural deal with Sanofi
Tuesday, 23 Feb 2016 07:30am EST 

Merus Labs International Inc:Has entered into an agreement with Sanofi S.A. to acquire the rights to Surgestone, Provames, Speciafoldine, and Tredemine in France.Merus acquired the product rights for a one-time payment of EUR22.5 million.Says net revenue for the products in 2016 is expected to be approximately EUR6.3 million.At current exchange rates, the products are expected to generate approximately $5.6 million in annual EBITDA.Revised guidance for adjusted EBITDA during fiscal year ending September 30, 2016 to be $47 million to $50 million.Says acquisition is expected to be funded with one third debt and two thirds equity.  Full Article

More From Around the Web

BRIEF-Merus Labs responds to Reuters News article

* Currently using Rothschild to provide investment banking and financial advisory services